CHEST Physician
-
Short-course all-oral therapy appears effective, safe for resistant TB
Patrick PJ Phillips, PhD, said the noninferiority BEAT Tuberculosis trial showed a six-month treatment strategy could achieve outcomes similar to those of longer, standard regimens.
-
Ensitrelvir cuts COVID-19 risk by two-thirds after household exposure
Paul E. Sax, MD, said postexposure prophylaxis may be a useful addition to vaccination, testing, and treatment, particularly in populations at high-risk of severe disease.
-
Study evaluates amivantamab plus lazertinib for EGFR-mutant NSCLC with CNS metastases
With the combination now available, Mark Jeng, MD, PhD, revisits positive results from a recent study evaluating the strategy in this high-risk population.
-
When everyone nods but no one understands
As critical care evolves, one of our greatest responsibilities is to ensure that patients and families have a clear and comprehensive understanding of their condition and care plan.
-
Using gastric POCUS in the ICU for aspiration risk assessment
In an era of increasing GLP-1 receptor agonist use and frequent emergency airway interventions, gastric POCUS provides clinically actionable information that fasting history alone cannot.
-
Bronchiectasis: Bridging the gap between guidelines and real-world care
The measure of a guideline is not how comprehensively it describes ideal care but how consistently its recommendations reach the patients who need them.
-
AI in home mechanical ventilation: Friend or foe?
Pulmonary medicine has not developed a shared language for home mechanical ventilation, which limits the application of artificial intelligence in patient care.
-
Leadership begins before the title
CHEST President Neil Freedman, MD, FCCP, discusses what makes a strong leader and how CHEST can help set clinicians on that path.
-
FDA warning on montelukast linked to prescription decline for asthma
Sami Hossri, MD, FCCP, said that while data show the warning prompted an immediate and sharp drop in new prescriptions, the shift in overall use was more modest.
-
MARCH trial challenges routine use of mucoactive therapies in mechanically ventilated patients
Jesse Hall, MD, said the safety findings revealed “clinically significant events and tip the balance from ‘no benefit’ to ‘no benefit and likely harms.’”
